Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). (Q30784225)

26 June 2017

Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). (English)

1 reference

26 June 2017

0 references

1 reference

European Nicotinamide Diabetes Intervention Trial Group

series ordinal

1

1 reference

PubMed ID

12687331

26 June 2017

language of work or name

1 reference

27 February 2003

1 reference

26 June 2017

1 reference

26 June 2017

46

1 reference

26 June 2017

3

1 reference

26 June 2017

339-346

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-003-1033-8

26 June 2017

0 references

cites work

Measurement of N-methyl-2-pyridone-5-carboxamide in urine by high performance liquid chromatography

1 reference

12 December 2020

Effects of insulin in relatives of patients with type 1 diabetes mellitus

1 reference

12 December 2020

Does partial preservation of residual beta-cell function justify immune intervention in recent onset Type I diabetes?

1 reference

12 December 2020

A novel micro-assay for insulin autoantibodies

1 reference

12 December 2020

Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes

1 reference

12 December 2020

Enzyme immunoassay for intact human insulin in serum or plasma

1 reference

12 December 2020

Nicotinamide and insulin secretion in normal subjects

1 reference

12 December 2020

Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies

1 reference

12 December 2020

Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis

1 reference

12 December 2020

Prevention or delay of Type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide

1 reference

12 December 2020

Islet autoantibodies, nationality and gender: a multinational screening study in first-degree relatives of patients with Type I diabetes

1 reference

12 December 2020

Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials

1 reference

12 December 2020

Standardization of IVGTT to predict IDDM

1 reference

12 December 2020

Measurement of nicotinamide and N-methyl-2-pyridone-5-carboxamide in plasma by high performance liquid chromatography

1 reference

12 December 2020

Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group

1 reference

12 December 2020

Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop

1 reference

12 December 2020

Is there a role for nitric oxide in beta-cell dysfunction and damage in IDDM?

1 reference

12 December 2020

Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin.

1 reference

12 December 2020

Record-high incidence of Type I (insulin-dependent) diabetes mellitus in Finnish children. The Finnish Childhood Type I Diabetes Registry Group.

1 reference

12 December 2020

Comparison of bolus and infusion protocols for determining acute insulin response to intravenous glucose in normal humans. The ICARUS Group. Islet Cell Antibody Register User's Study

1 reference

12 December 2020

The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group.

1 reference

12 December 2020

Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group

1 reference

12 December 2020

Safety of high-dose nicotinamide: a review

1 reference

12 December 2020

HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection

1 reference

12 December 2020

Nicotinamide in type 1 diabetes. Mechanism of action revisited.

1 reference

12 December 2020

Nicotinamide--biological actions and therapeutic potential in diabetes prevention. IDIG Workshop, Copenhagen, Denmark, 4-5 December 1992.

1 reference

12 December 2020

Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers

1 reference

12 December 2020

Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study

1 reference

12 December 2020

Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

1 reference

12 December 2020

Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM

1 reference

12 December 2020

Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives

1 reference

12 December 2020

Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity

1 reference

12 December 2020

10.1007/S00125-003-1033-8

Identifiers

DOI

1 reference

PubMed ID

12687331

Dimensions Publication ID

26 June 2017

0 references

1 reference

PubMed ID

12687331